CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely limited – only 2 in 10 eligible patients receive this potential curative therapy. Barriers include geographic concentration of treatment centers, complex referral and authorization processes, high financial and logistical burdens for patients and caregivers, and systemic challenges in care coordination and reimbursement. While clinical and policy progress has improved safety and delivery models, urgent action is needed to close the access gap.

As CAR T indications expand beyond blood cancers into solid tumors, autoimmune, and inflammatory diseases, the number of eligible patients who would benefit from CAR T will increase in parallel. Growth in this space underscores the need to modernize health systems and reform financing and delivery models to ensure access is not constrained by geography, infrastructure, or outdated payment structures. This paper outlines strategies to promote timely access, reduce patient and caregiver strain, expand treatment capacity beyond academic medical centers, and modernize health system infrastructure and financing to ensure sustainable delivery of advanced therapies.

View the full whitepaper here:

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care, was made possible through funding provided by Kite, a Gilead company.

ADVI offers expert advice and influential solutions, informed by data and guided by a clear vision of the complex intersection of life sciences/healthcare innovation, economics, policy, and patient impact. Get in touch to receive cell and gene insights from our Policy, Research, and Analysis team.